Rush to Develop ‘Chemically Modified Drug’ of Amosartan
Many pharmaceutical companies rush to develop chemically modified drug of antihypertension that is modeled on Hanmi Amosartan.
They have been launching forth on commercialization with the goal of a license after the PMS expiration date of Amorsartan which is March 30, 2015.
On September 11, acc...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
